海创药业涨超10%，前沿生物涨超8%，悦康药业、热景生物、回盛生物、众生药业跟涨。 (本文来自第一财经) 海创药业涨超10%，前沿生物涨超8%，悦康药业、热景生物、回盛生物、众生药业跟涨。 (本文来自第一财经) ...

- The report suggests that the short-term correction pressure in the A-share market may have been released, and the market has re-entered a volatile range[1][12] - The report recommends using "dividends + technology" as the main allocation strategy, with dividends potentially having an advantage in terms of volatility[1][12] - The report tracks the performance of major broad-based indices, noting that the Shanghai Composite Index rose by 0.37%, the Shanghai 50 by 1.09%, the CSI 300 by 1.28%, the CSI 500 by 0.94%, the CSI 1000 by 0.11%, the ChiNext Index by 1.86%, and the Beijing 50 Index by 1.49% during the week of December 1-5, 2025[1][13][14] - The valuation of broad-based indices as of December 5, 2025, shows that the CSI 500, CSI 1000, and ChiNext Index are at "moderate" levels, while the Shanghai Composite Index, Shanghai 50, and CSI 300 are at "dangerous" levels[1][19][20] - The report tracks quantitative sentiment indicators, including volume timing signals, which are all cautious as of December 5, 2025[24][25] - The report discusses the "number of rising stocks in the CSI 300" sentiment indicator, which is used to gauge market sentiment by calculating the proportion of stocks with positive returns over a certain period[25][26] - The report evaluates the "moving average sentiment indicator," which uses the eight moving average system to judge the trend state of the CSI 300 index[33][36] - The report observes market profitability effects through cross-sectional volatility and time series volatility, noting that the short-term Alpha environment has improved for the CSI 300 and CSI 500 indices but worsened for the CSI 1000 index[37][38][39][40] - The report tracks institutional research activities, noting that the top five stocks receiving the most attention from institutions during the week were Jereh Co., Ltd., Yihada, Hotgen Biotech, Espressif Systems, and Changan Automobile[41][42][53][54] - The report tracks the performance of stock index futures, noting that the main contracts for IF, IH, IC, and IM all rose during the week, with varying degrees of basis changes[56][57][58][59] - The report tracks southbound capital flows, noting a net inflow of HKD 113.49 billion during the week of December 1-5, 2025[66][68] - The report tracks changes in financing scale, noting that the financing balance as of December 4, 2025, was CNY 24,664.89 billion, an increase of CNY 99.89 billion from November 28, 2025[67][72] - The report tracks the ETF market, noting that stock ETFs had a median return of 1.06% and a net inflow of CNY 25.94 billion during the week, while cross-border ETFs had a median return of 0.48% and a net inflow of CNY 12.67 billion[69][70][71] - The report tracks the degree of fund concentration, noting that the degree of fund concentration decreased slightly from the previous week, while the excess returns of concentrated stocks and funds increased from the previous week[77][79][80]

Core Viewpoint - The company, 热景生物, is significantly increasing its investment in 舜景医药 and 尧景基因, aiming to strengthen its position in the innovative drug sector while facing challenges in its core IVD business [1][4][10]. Investment Plans - 热景生物 plans to invest 371 million yuan in 舜景医药, increasing its stake from 43.18% to 50.23% and gaining control through board restructuring [1][4]. - The company will also invest 24 million yuan in 尧景基因 to enhance its gene technology capabilities [4][14]. - 舜景医药 is set to implement a 40 million yuan equity incentive plan [4]. Stock Performance - Following the announcement of these investment plans, 热景生物's stock price rose by 2.52% to 183.3 yuan per share, with an increase of over 900% since September 2024 [4][13]. - The company's market capitalization reached approximately 16.993 billion yuan [13]. Business Strategy - 热景生物 is pursuing a dual-driven strategy of "diagnostics + innovative drugs," focusing on antibody and nucleic acid drugs [6][7]. - The company aims to counteract the downward pressure in the IVD industry by diversifying into the innovative drug sector [11]. Financial Performance - In the first three quarters of 2025, 热景生物 reported a revenue of 310 million yuan, a year-on-year decrease of 19.8%, and a net loss of 109 million yuan, which is a 168.12% increase in losses compared to the previous year [10]. - The company's revenue has significantly declined from 5.14 billion yuan in 2020 to 5.41 million yuan in 2023, with a projected further decline to 5.11 billion yuan in 2024 [10][11]. Challenges in the IVD Industry - The IVD industry is experiencing a downturn due to policy impacts, leading to a 13.94% revenue decline and a 32.20% drop in net profit across the sector [11]. - Over 70% of IVD companies are expected to report losses in 2025, with a cumulative loss exceeding 5.6 billion yuan [11]. R&D and Future Prospects - 舜景医药 is in the early stages of development, with no profitable products yet, but has promising drug candidates like SGC001 for acute myocardial infarction [7][8]. - The company has reduced its R&D investment from 191 million yuan in 2022 to 113 million yuan in 2024, raising concerns about its ability to support innovative drug development [12].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 北京热景生物技术股份有限公司（以下简称"公司"）重要参股公司杭州翱锐生物科技有限公司（以下简 称"翱锐生物"）近期获得独立分析软件的国内III类医疗器械注册证。相关信息如下： 一、获得资质的具体情况 （一）获得国内医疗器械注册证情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688068 证券简称：热景生物 公告编号：2025-087 北京热景生物技术股份有限公司 关于公司参股公司近期 获得资质情况的自愿披露公告 上述资质的取得，从医疗器械独立分析软件方面，丰富了公司肿瘤检测产品的种类，进一步完善了肝癌 检测相关产品系列，便于进一步提高公司的市场拓展能力，提升公司核心竞争力。 三、风险提示 上述产品的实际销售情况取决于市场的推广效果、同类竞争产品的销售以及产品需求等多重因素影响， 具有较大的不确定性。敬请广大投资者注意投资风险。公司将继续加大对产品的研发投入，不断向市场 推出对人类健康和生命有显著价值的产品，全力以赴做好公司经营。 特此公告。 北京热景生物技 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-088 北京热景生物技术股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/11/12 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 2025 12 11 | 11 | 月 | 日~2026 | 年 | 月 | 11 | 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 904,054股 | | | | | | | | | 累计已回购股数占总股本比例 | 0.98% | | | | | | | | | ...

证券代码：688068 证券简称：热景生物 公告编号：2025-087 | | | 国械注准 | | | | 国家药品 | | --- | --- | --- | --- | --- | --- | --- | | | OTX1、PTPN18、HIST1H3G | 20253212452 | III | 2025/12/1 | 2030/11/30 | 监督管理局 | | 序号 1 | 产品名称 TSPYL5、RASSF1A、DAB2IP、 基因甲基化检测分析软件 | 注册证号 | 类别 | 发证日期 | 有效期至 | 发证机构 | 适用范围：本产品配套杭州翱锐基因科技有限公司的 TSPYL5、RASSF1A、 DAB2IP、OTX1、PTPN18、HIST1H3G 基因甲基化检测试剂盒（PCR 荧光探针 法）（国械注准 20253402195）使用，适用于临床上对疑似原发性肝癌的辅助诊 断，包括临床肝区影像学检查和既有临床检查怀疑肝占位性病变的患者。软件对 试剂盒检测所获得的人血浆游离 DNA(cfDNA）中甲基化的上述六个靶点的结果 （各基因的 Ct 值）进行计算分析，判断检测结果的阴性和阳性。 二、对公 ...

Core Points - The Shanghai Composite Index closed at 3892.55 points, above the five-day moving average, with a decline of 0.55% [1] - The total trading volume of A-shares reached 1,056.036 billion yuan, with 192 A-shares breaking through the five-day moving average [1] Summary by Category Stock Performance - Notable stocks with significant deviation rates above the five-day moving average include: - Zhaobiao Co., Ltd. (301136) with a deviation rate of 15.44% and a daily increase of 20.00% [1] - Jianglong Shipbuilding (300589) with a deviation rate of 7.81% and a daily increase of 9.75% [1] - Haixiang New Materials (003011) with a deviation rate of 7.17% and a daily increase of 10.02% [1] Trading Activity - The trading turnover rate for Zhaobiao Co., Ltd. was 15.73%, indicating high trading activity [1] - Other stocks with notable trading turnover rates include Jianglong Shipbuilding at 35.06% and Haixiang New Materials at 8.58% [1] Market Trends - The overall market showed a mixed performance with some stocks significantly outperforming the five-day moving average while others just managed to cross it [1]

丨 2025年12月2日星期二丨 NO.1 复宏汉霖PD-L1 ADC II期结果读出 NO.3 热景生物与关联方共同投资尧景基因 北京热景生物技术股份有限公司、林长青、北京尧景企业管理中心（有限合伙）拟共同对北京尧景基因 技术有限公司（以下简称"尧景基因"）进行增资，增资方案为热景生物出资2400万元，林长青出资5000 万元，尧景合伙出资600万元，合计出资8000万元，按照2元/注册资本的价格进行增资。本次增资完成 后，尧景基因注册资本由11000万元变更为15000万元，公司持有尧景基因的股权比例由40.91%变更为 38.00%。 11月26日， 复宏汉霖发布公告表示将在ESMO Asia 2025大会上公布多项药物的临床数据。亮点之一在 于核心资产PD-L1 ADC药物HLX43在宫颈癌领域的II期研究结果。 点评：针对PD-L1 ADC开发在研管线并不多，目前进度最快的是辉瑞的PF-08046054，已至临床III期。 除此之外，HLX43开发领先。 NO.2 *ST苏吴进入退市整理期 江苏吴中医药发展股份有限公司于2025年12月1日收到上海证券交易所出具的《关于江苏吴中医药发展 股份有限公司 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-085 登录新浪财经APP 搜索【信披】查看更多考评等级 北京热景生物技术股份有限公司 关于与关联方共同投资尧景基因 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 交易概述：北京热景生物技术股份有限公司（以下简称"公司"或"热景生物"）、林长青、北京尧景企 业管理中心（有限合伙）（以下简称"尧景合伙"）拟共同对北京尧景基因技术有限公司（以下简称"尧 景基因"）进行增资，增资方案为热景生物出资2,400万元，林长青出资5,000万元，尧景合伙出资600万 元，合计出资8,000万元，按照2元/注册资本的价格进行增资。本次增资完成后，尧景基因注册资本由 11,000万元变更为15,000万元，公司持有尧景基因的股权比例由40.91%变更为38.00%。 ● 本次增资方林长青为公司控股股东、实际控制人、董事长兼总经理；增资方北京尧景企业管理中心 （有限合伙）为林长青担任执行事务合伙人、公司董事柳晓利、许立达及公司副总经理兼董事 ...

Group 1 - The company plans to increase its investment in Beijing ShunJing Biopharmaceutical Technology Co., Ltd. by 371 million yuan at a price of 26.5 yuan per registered capital, acquiring 400,000 shares from Lishui Qiaoda Venture Capital Partnership [1] - Following the investment and share acquisition, the company's ownership in ShunJing Biopharmaceutical will rise from 43.1842% to 50.234%, making it a controlling subsidiary [1] - The company intends to implement a stock incentive plan to motivate the core team and key personnel of ShunJing Biopharmaceutical, with an additional investment of 40 million yuan at a price of 10 yuan per registered capital [1] Group 2 - The company announces a capital increase in Beijing YaoJing Gene Technology Co., Ltd. totaling 80 million yuan, with contributions from the company, Lin Changqing, and YaoJing Partnership [2] - The company will invest 24 million yuan, while Lin Changqing will contribute 50 million yuan, and YaoJing Partnership will invest 6 million yuan at a price of 2 yuan per registered capital [2] - After the capital increase, the company's ownership in YaoJing Gene will decrease from 40.91% to 38% [2]